Healios K.K. (HLOSF) Stock Price, News & Analysis

Company Overview

Healios K.K. is a Japan-based biotechnology company focused on developing regenerative medicines and cell therapies. The company’s research centers on pluripotent stem cells, including induced pluripotent stem cells (iPSCs), and somatic stem cells intended to treat conditions for which existing therapies may be limited.

Healios has developed programs using iPSC-derived cells for ophthalmic diseases, including retinal disorders, and is also advancing cell therapy candidates for acute neurological and other serious medical conditions. One of its key programs is based on allogeneic bone-marrow-derived cells licensed from Athersys, intended for potential use in conditions such as ischemic stroke and acute respiratory distress syndrome. These candidates remain subject to clinical testing and regulatory review unless otherwise approved.

Founded in Japan in 2011, Healios conducts its research and clinical development activities primarily in Japan while maintaining relationships with overseas technology providers and development partners. The company’s work includes the manufacture, testing, and clinical evaluation of regenerative medicine products, with the goal of addressing unmet medical needs through off-the-shelf cell therapies.

Key Stats

• Today's Range: $1.80 to $1.80
• 50-Day Range: $1.80 to $1.80
• 52-Week Range: $1.80 to $4.45
• Volume: N/A
• Average Volume: 300 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/29/2026
• Next Earnings (Estimated): 11/12/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:HLOSF
• CIK: N/A
• Web: healios.co.jp
• Phone: 81357778308
• Fax: N/A
• Employees: 75
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A